{"id":"W2977936382","doi":"10.1093/annonc/mdz394.007","title":"Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Human Epidermal Growth Factor Receptor 2; Oncology; Internal medicine; Hormone receptor; Cancer; Breast cancer; Gynecology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002700688,0.0005145223,0.001720283,0.000161972,0.00009242746,0.000004866887,0.0003142767,0.0002372271,0.0001778364],"category_scores_gemma":[0.00008384008,0.0003250259,0.0002003761,0.0004345305,0.0009177456,0.0003357616,0.00008132649,0.0004232539,0.00000279693],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002394006,"about_ca_system_score_gemma":0.0006288749,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002292084,"about_ca_topic_score_gemma":0.0003813487,"domain_scores_codex":[0.9964244,0.0004199679,0.001131675,0.0006444446,0.0007815576,0.0005979488],"domain_scores_gemma":[0.9950817,0.000482186,0.001861434,0.0005686441,0.001802996,0.0002030313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.835449,0.006105245,0.01483226,0.0001352405,0.002254465,0.00002597249,0.002566282,0.0001279773,0.1145817,0.0002409229,0.0001227796,0.02355808],"study_design_scores_gemma":[0.3780646,0.08251876,0.4071865,0.0005431062,0.0003739771,0.00003710618,0.000500751,0.000009256731,0.1298383,0.0001196713,0.0003473076,0.0004606796],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903712,0.0001546646,0.00001309765,0.001422639,0.0001732853,0.00262821,0.003786593,0.00003175746,0.001418511],"genre_scores_gemma":[0.9984621,0.0001651403,0.0002924719,0.0002809413,0.0001222597,0.00009709583,0.0002182289,0.00007319653,0.0002885427],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4573845,"threshold_uncertainty_score":0.9999202,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02761816145389646,"score_gpt":0.3378950834321779,"score_spread":0.3102769219782814,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}